Business
Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials
The Orthocell Ltd (ASX: OCC) share price is 17% higher this morning, after the company released positive results in its CelGro nerve repair study. At the time of writing, Orthocell shares are trading at 44 cents per share.
About Orthocell
Orthocell is a regenerative medicine company dedicated to the development of novel collagen medical devices and cellular therapies for the repair and regeneration of human tendons, bone, nerve and cartilage defects.
The company’s regenerative medicine products include CelGro, a naturally derived collagen medical device for tissue repair. CelGro is designed for use in multiple indications to augment the surgical repair of tendons, bone, peripheral nerves and articular cartilage.
The product…
-
Noosa News15 hours agoProtest calls for shark net removal
-
Noosa News17 hours agoNew playground equipment encourages children to learn through ‘risky play’
-
General14 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania
-
Noosa News8 hours agoPrime Minister Anthony Albanese calls for political temperature to be ‘turned down’ after alleged death threat